Search - tctmd.com

Displaying 21 - 36 of 36

Sort: Relevancy | Date

Presentation TCT 2024

TCT 446: Long-term Outcomes and Impact of Diabetes Mellitus in Patients Treated With Paclitaxel Coated Balloon for Drug-Eluted Stent Restenosis

Presenter: Gakuto Bando

October 28, 2024

News Opinion Editor's Corner TCT 2024

What’s Going to Be Big at TCT 2024?

Michael O'Riordan

October 17, 2024

News Conference News ESC 2024

REC-CAGEFREE I: DCB Fails to Match Up to DES for De Novo CAD

Todd Neale

September 09, 2024

News Daily News

FDA Medical Devices Chief Jeff Shuren Announces Retirement

L.A. McKeown

July 24, 2024

News Industry News

Cordis Announces Positive 24-Month Results from Superficial Femoral Artery Study, Confirming Sustained Benefits of SELUTION SLR™ (sustained limus release) Drug-Eluting Balloon in Complex Patients

June 18, 2024

Podcast TCTMD Talking Points

The AGENT IDE Trial

June 05, 2024

News Conference News EuroPCR 2024

Stepwise DAPT De-escalation Shows Promise in DCB-Only PCI for ACS

Yael L. Maxwell

May 15, 2024

Presentation EuroPCR 2024

Sirolimus vs paclitaxel DCB. A logistic regression analysis of EASTBOURNE and PEARL multicentre study

Presenter: Bernardo Cortese

May 14, 2024

News Daily News

As US Rollout Begins for Coronary DCBs, Interventionalists Mull Practice Changes

Todd Neale

May 03, 2024

News Daily News

BASIL-3: More Questions Than Answers About Drug-Coated Devices in CLTI

L.A. McKeown

April 24, 2024

News Daily News

DCB in STEMI Match DES Through 5 Years: REVELATION

Caitlin E. Cox

March 27, 2024

News Daily News

DETECT: No Long-term Harm From Paclitaxel Devices in PAD

L.A. McKeown

March 25, 2024

News Conference News CRT 2024

Mixed Bag With DCBs for In-Stent Restenosis, Small Coronary Arteries

L.A. McKeown

March 14, 2024

News Conference News CRT 2024

Full AGENT IDE Results Affirm Benefits of DCB for In-Stent Restenosis

L.A. McKeown

March 09, 2024

News Daily News

Agent Coronary DCB Gets FDA Approval for In-Stent Restenosis

L.A. McKeown

March 01, 2024

Presentation Miami Valves 2024

Multicenter Randomized Trial Comparing the AGENT Paclitaxel-Coated Balloon With Conventional Balloon Angioplasty for In-Stent Restenosis

Presenter: Thomas E. Noel

February 01, 2024

Advertisement

TCT 446: Long-term Outcomes and Impact of Diabetes Mellitus in Patients Treated With Paclitaxel Coated Balloon for Drug-Eluted Stent Restenosis

What’s Going to Be Big at TCT 2024?

REC-CAGEFREE I: DCB Fails to Match Up to DES for De Novo CAD

FDA Medical Devices Chief Jeff Shuren Announces Retirement

Cordis Announces Positive 24-Month Results from Superficial Femoral Artery Study, Confirming Sustained Benefits of SELUTION SLR™ (sustained limus release) Drug-Eluting Balloon in Complex Patients

The AGENT IDE Trial

Stepwise DAPT De-escalation Shows Promise in DCB-Only PCI for ACS

Sirolimus vs paclitaxel DCB. A logistic regression analysis of EASTBOURNE and PEARL multicentre study

As US Rollout Begins for Coronary DCBs, Interventionalists Mull Practice Changes

BASIL-3: More Questions Than Answers About Drug-Coated Devices in CLTI

DCB in STEMI Match DES Through 5 Years: REVELATION

DETECT: No Long-term Harm From Paclitaxel Devices in PAD

Mixed Bag With DCBs for In-Stent Restenosis, Small Coronary Arteries

Full AGENT IDE Results Affirm Benefits of DCB for In-Stent Restenosis

Agent Coronary DCB Gets FDA Approval for In-Stent Restenosis

Multicenter Randomized Trial Comparing the AGENT Paclitaxel-Coated Balloon With Conventional Balloon Angioplasty for In-Stent Restenosis

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content